Streetbeat News

Analyst Ratings

LH

Laboratory Corp (NYSE:LH) has received 5 analyst ratings in the last quarter, with 3 being bullish and 2 somewhat bullish. The average price target is $275.0, implying an upside from the current price of $213.83. This average has decreased by 2.83% from the previous average price target of $283.00.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 4:01 pm

HSBC

HSBC Holdings Inc. (NYSE:HSBC) stock has seen a 1.35% spike in the current session, a 5.44% increase over the past month, and a 24.94% increase over the past year. Despite this performance, the company's P/E ratio is lower than the aggregate P/E of 9.48 of the Banks industry, which could indicate that the stock is undervalued or that shareholders do not expect future growth.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 4:00 pm

EYPT

EyePoint Pharmaceuticals (NASDAQ:EYPT) has received mostly bullish ratings from analysts in the last quarter, with 6 bullish and 1 somewhat bullish ratings. The average 12-month price target for the company is $30.71, a decrease of 6.0% from the previous average of $32.67.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 4:00 pm

PCOR

Procore Technologies (NYSE:PCOR) has received 9 bullish analyst ratings in the last quarter, with an average price target of $79.56, indicating an upside from the current price of $73.18. This average price target has increased by 12.06% from the previous average of $71.00.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 4:00 pm

LSTR

Stephens & Co. analyst Jack Atkins has maintained an Equal-Weight rating on Landstar System (NASDAQ:LSTR) and raised the price target from $200 to $210.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 28, 2023 | 3:58 pm

TCBX

Stephens & Co. analyst Matt Olney maintains an Overweight rating on Third Coast Bancshares (NASDAQ:TCBX) and raises the price target from $19 to $24.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 28, 2023 | 3:56 pm

BIIB

DSGN

LRMR

RETA

SLDB

Biogen Inc has agreed to acquire Reata Pharmaceuticals Inc for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Analysts from William Blair view the acquisition as fitting Biogen's acquisition goals of de-risked, value-added and accretive assets. They also acknowledged potential competition from other clinical-stage programs, including Larimar Therapeutics Inc, Design Therapeutics Inc, and Solid Biosciences Inc. The deal, if finalized in Q4, would consume the majority of Biogen's $10 billion allocation for corporate acquisitions.

Portfolio Pulse from Vandana Singh

July 28, 2023 | 3:56 pm

SQ

Exane BNP has upgraded Block's stock from Underperform to Outperform and set a new price target of $95. This has led to an increase in the trading of Block shares.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 3:55 pm

BMY

Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Bristol-Myers Squibb (NYSE:BMY) and lowered the price target from $78 to $65.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 3:55 pm

SLM

Stephens & Co. analyst Vincent Caintic maintains an Equal-Weight rating on SLM (NASDAQ:SLM) and raises the price target from $15 to $17.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 28, 2023 | 3:54 pm